Abstract
Cholinergic dysfunction is a major feature of dementia with Lewy bodies (DLB) and makes a significant contribution to the cognitive impairment and other challenging symptoms seen in this condition. Despite this, or indeed, because of this, manipulation of the cholinergic system can offer significant therapeutic opportunities for treating DLB, and this is reflected in the fact that cholinesterase inhibitors remain one of our best treatments in this condition. In this chapter, we will explore the pathology of cholinergic dysfunction in DLB, review findings from both post-mortem and imaging studies and place this within a clinical framework.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40. doi:10.1016/s0140-6736(13)62106-6.
Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep. 2012;12(5):492–501. doi:10.1007/s11910-012-0290-7.
Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci. 1983;59(2):277–89.
Perry RH, Tomlinson BE, Candy JM, et al. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet. 1983;2(8353):789–90.
Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221(2):564–73. doi:10.1016/j.bbr.2009.12.048.
Hall H, Reyes S, Landeck N, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014;137(Pt 9):2493–508. doi:10.1093/brain/awu193.
Liu AK, Chang RC, Pearce RK, et al. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129(4):527–40. doi:10.1007/s00401-015-1392-5.
Chui HC, Mortimer JA, Slager U, et al. Pathologic correlates of dementia in Parkinson’s disease. Arch Neurol. 1986;43(10):991–5.
Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1985;48(5):413–21.
Alexandris A, Liu AK, Chang RC, et al. Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders. Acta Neuropathol Commun. 2015;3:77. doi:10.1186/s40478-015-0249-4.
Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer’s and Parkinson’s disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol. 1988;273(4):543–57. doi:10.1002/cne.902730409.
Cullen KM, Halliday GM. Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. Neurobiol Aging. 1998;19(4):297–306.
Mattila PM, Roytta M, Lonnberg P, et al. Choline acetytransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol (Berl). 2001;102(2):160–6.
Piggott MA, Owens J, O’Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease. J Chem Neuroanat. 2003;25(3):161–73.
Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience. 1995;64(2):385–95.
Court J, Spurden D, Lloyd S, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 1999;73(4):1590–7.
Sahin HA, Emre M, Ziabreva I, et al. The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 2006;111(2):115–25. doi:10.1007/s00401-005-0003-2.
Kalaitzakis ME, Walls AJ, Pearce RK, et al. Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes. Neurobiol Dis. 2011;41(2):377–84. doi:10.1016/j.nbd.2010.10.005.
Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience. 2000;98(1):79–87.
Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology. 2004;29(1):108–16.
Ray M, Bohr I, McIntosh JM, et al. Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. Neurosci Lett. 2004;372(3):220–5. doi:10.1016/j.neulet.2004.09.042.
Bohr IJ, Ray MA, McIntosh JM, et al. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus. Exp Neurol. 2005;191(2):292–300. doi:10.1016/j.expneurol.2004.10.004.
Gotti C, Moretti M, Bohr I, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis. 2006;23(2):481–9. doi:10.1016/j.nbd.2006.04.005.
Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(1):7–16. doi:10.1136/jnnp-2013-305062.
Delli Pizzi S, Maruotti V, Taylor JP, et al. Relevance of subcortical visual pathways disruption to visual symptoms in dementia with Lewy bodies. Cortex. 2014;59:12–21. doi:10.1016/j.cortex.2014.07.003.
Delli Pizzi S, Franciotti R, Taylor JP, et al. Thalamic involvement in fluctuating cognition in Dementia with Lewy Bodies: magnetic resonance evidences. Cerebral Cortex (New York: 1991). 2015;25(10):3682–9. doi:10.1093/cercor/bhu220.
Ziabreva I, Ballard CG, Aarsland D, et al. Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging. 2006;27(3):433–8.
Kotagal V, Muller ML, Kaufer DI, et al. Thalamic cholinergic innervation is spared in Alzheimer disease compared to Parkinsonian disorders. Neurosci Lett. 2012;514(2):169–72. doi:10.1016/j.neulet.2012.02.083.
Seidel K, Mahlke J, Siswanto S, et al. The brainstem pathologies of Parkinson’s disease and dementia with Lewy bodies. Brain Pathol. 2015;25(2):121–35. doi:10.1111/bpa.12168.
Schmeichel AM, Buchhalter LC, Low PA, et al. Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology. 2008;70(5):368–73. doi:10.1212/01.wnl.0000298691.71637.96.
Dugger BN, Murray ME, Boeve BF, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol Appl Neurobiol. 2012;38(2):142–52. doi:10.1111/j.1365-2990.2011.01203.x.
Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain. 2000;123(Pt 9):1767–83.
Janzen J, van ‘t Ent D, Lemstra AW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol. 2012;259(1):147–54. doi:10.1007/s00415-011-6149-z.
Park HE, Park IS, Oh YS, et al. Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism. J Neurol Sci. 2015;353(1–2):44–8. doi:10.1016/j.jns.2015.03.046.
Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410.
Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65(11):1716–22. doi:10.1212/01.wnl.0000191154.78131.f6.
Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73(4):273–8. doi:10.1212/WNL.0b013e3181ab2b58.
Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885–92. doi:10.1212/WNL.0b013e3181d55f61.
Marcone A, Garibotto V, Moresco RM, et al. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer’s disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis. 2012;31(2):387–99. doi:10.3233/JAD-2012-111748.
O’Brien JT, Colloby SJ, Pakrasi S, et al. Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage. 2008;40(3):1056–63. doi:10.1016/j.neuroimage.2008.01.010.
Colloby SJ, Perry EK, Pakrasi S, et al. Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer’s disease and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2010;18(1):86–90. doi:10.1097/JGP.0b013e3181b972aa.
Isaias IU, Spiegel J, Brumberg J, et al. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson’s disease. Front Aging Neurosci. 2014;6:213. doi:10.3389/fnagi.2014.00213.
Colloby SJ, Pakrasi S, Firbank MJ, et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia. NeuroImage. 2006;33(2):423–9.
Colloby S, McKeith I, Burn D, et al. Cholinergic and perfusion brain networks in Parkinson’s disease dementia. Neurology. 2016; pii: 10.1212/WNL.0000000000002839. [Epub ahead of print]
Kim HJ, Lee JE, Shin SJ, et al. Analysis of the substantia innominata volume in patients with Parkinson’s disease with dementia, dementia with Lewy bodies, and Alzheimer’s disease. J Mov Disord. 2011;4(2):68–72. doi:10.14802/jmd.11014.
Grothe MJ, Schuster C, Bauer F, et al. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia. J Neurol. 2014;261(10):1939–48. doi:10.1007/s00415-014-7439-z.
Colloby SJ, Elder GJ, Rabee R, et al. Structural grey matter changes in the substantia innominata in Alzheimer’s disease and dementia with Lewy bodies: a DARTEL-VBM study. Int J Geriatr Psychiatry. 2016. doi:10.1002/gps.4500.
Satoh M, Ishikawa H, Meguro K, et al. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64(6):337–44. doi:10.1159/000322121.
Fong T, Inouye S, Dai W, et al. Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? Brain Imag Behavior. 2010;5(1):25–35. doi:10.1007/s11682-010-9108-x.
Gratwicke J, Kahan J, Zrinzo L, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev. 2013;37(10 Pt 2):2676–88. doi:10.1016/j.neubiorev.2013.09.003.
Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138(Pt 6):1454–76. doi:10.1093/brain/awv104.
Collerton D, Burn D, McKeith I, et al. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord. 2003;16(4):229–37.
Hanyu H, Asano T, Sakurai H, et al. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol. 2002;23(1):27–32.
Choi SH, Jung TM, Lee JE, et al. Volumetric analysis of the substantia innominata in patients with Parkinson’s disease according to cognitive status. Neurobiol Aging. 2012;33(7):1265–72. doi:10.1016/j.neurobiolaging.2010.11.015.
Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253(2):242–7.
Lorenz R, Samnick S, Dillmann U, et al. Nicotinic alpha4beta2 acetylcholine receptors and cognitive function in Parkinson’s disease. Acta Neurol Scand. 2014;130(3):164–71. doi:10.1111/ane.12259.
Kenny ER, Blamire AM, Firbank MJ, et al. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer’s disease. Brain. 2012;135(Pt 2):569–81. doi:10.1093/brain/awr327.
Peraza LR, Kaiser M, Firbank M, et al. fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. NeuroImage Clinical. 2014;4:558–65. doi:10.1016/j.nicl.2014.03.013.
Peraza LR, Taylor JP, Kaiser M. Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging. 2015;36(9):2458–67. doi:10.1016/j.neurobiolaging.2015.05.015.
Dauwan M, van Dellen E, van Boxtel L, et al. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer’s disease and controls. Neurobiol Aging. 2016;41:122–9. doi:10.1016/j.neurobiolaging.2016.02.017.
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology. 2005;65:1863–72.
Ballard C, Aarsland D, Francis P, et al. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging. 2013;30(8):603–11. doi:10.1007/s40266-013-0092-x.
Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol. 2000;48(6):868–76.
Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav. 2001;70(4):571–9.
Teaktong T, Piggott MA, McKeith IG, et al. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res. 2005;161(2):299–305.
Marra C, Quaranta D, Profice P, et al. Central cholinergic dysfunction measured “in vivo” correlates with different behavioral disorders in Alzheimer’s disease and dementia with Lewy body. Brain Stimul. 2012;5(4):533–8. doi:10.1016/j.brs.2011.08.009.
O’Brien JT, Colloby SJ, Pakrasi S, et al. Nicotinic [alpha]4[beta]2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. NeuroImage. 2008;40(3):1056–63.
Hepp DH, Ruiter AM, Galis Y, et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol. 2013;72(12):1162–70.
Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord. 2011;26(14):2496–503. doi:10.1002/mds.23932.
Onofrj M, Taylor JP, Monaco D, et al. Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behav Neurol. 2013;27(4):479–93. doi:10.3233/BEN-129022.
Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci. 2005;28(6):737–57.
Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: A systematic review and meta-analysis. Am J Psychiatry. 2015:appiajp201514121582. doi:10.1176/appi.ajp.2015.14121582.
Ballard CG, Court JA, Piggott M, et al. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn. 2002;11(3):461–74.
Pimlott SL, Piggott M, Ballard C, et al. Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiol Dis. 2006;1:50–6.
Bonanni L, Thomas A, Tiraboschi P, et al. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(3):690–705. doi:10.1093/brain/awm322.
Walker MP, Ayre GA, Cummings JL, et al. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry. 2000;177:252–6.
Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology. 2000;54(8):1616–25.
Gore RL, Vardy ER, O’Brien JT. Delirium and dementia with Lewy bodies: distinct diagnoses or part of the same spectrum? J Neurol Neurosurg Psychiatry. 2015;86(1):50–9. doi:10.1136/jnnp-2013-306389.
Taylor JP, Colloby SJ, McKeith IG, et al. Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in dementia with Lewy bodies. Int Psychogeriatrics/IPA. 2013;25(12):1917–28. doi:10.1017/S1041610213001488.
Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81(18):1611–6. doi:10.1212/WNL.0b013e3182a9f558.
Sarter M, Albin RL, Kucinski A, et al. Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol. 2014;257:120–9. doi:10.1016/j.expneurol.2014.04.032.
Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670–6. doi:10.1212/WNL.0b013e3181c1ded6.
Weathers SP, Kotagal V, Bohnen NI, et al. Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. Parkinsonism Relat Disord. 2014;20(1):13–6. doi:10.1016/j.parkreldis.2013.08.021.
Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain. 2012;135(Pt 9):2779–88. doi:10.1093/brain/aws207.
Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133(Pt 6):1747–54. doi:10.1093/brain/awq079.
Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015;138(Pt 3):653–63. doi:10.1093/brain/awu369.
Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport. 1994;5(7):747–9.
Graff-Radford J, Boeve BF, Pedraza O, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain. 2012;135(Pt 8):2470–7. doi:10.1093/brain/aws173.
Fong TG, Inouye SK, Dai W, et al. Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? Brain Imaging Behav. 2011;5(1):25–35. doi:10.1007/s11682-010-9108-x.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan KK
About this chapter
Cite this chapter
Taylor, JP., Collerton, D., LeBeau, F., Perry, E. (2017). Cholinergic Pathology in Dementia with Lewy Bodies. In: Kosaka, K. (eds) Dementia with Lewy Bodies. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55948-1_3
Download citation
DOI: https://doi.org/10.1007/978-4-431-55948-1_3
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55946-7
Online ISBN: 978-4-431-55948-1
eBook Packages: MedicineMedicine (R0)